Placebo News and Research

RSS

AHS provides updated assessment of treatments for acute migraine

The January issue of the American Headache Society journal Headache provides an updated assessment of the best treatments to use when a migraine attack occurs. The assessment will form the basis of new AHS treatment guidelines.

21 Jan 2015

LUME-Lung 1 shows QoL, symptoms benefits

LUME-Lung 1 trial patients’ reports of symptoms and health-related quality of life support the use of second-line nintedanib for the treatment of advanced non-small-cell lung cancer.

20 Jan 2015

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter Plc. and Actavis plc today announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia.

20 Jan 2015

Penn State researchers explore benefits of beet juice

Athletes who down beet juice before exercising to increase blood flow and improve performance may be surprised at the results of a recent study conducted at Penn State's Noll Laboratory. While beetroot juice rich in nitrates did not enhance muscle blood flow or vascular dilation during exercise, researchers found that it did "de-stiffen" blood vessels under resting conditions, potentially easing the workload of the heart.

20 Jan 2015

GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

GenSpera Inc. today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC).

16 Jan 2015

Researchers assess the effect of IPT for children with anaemia in malaria endemic regions

Researchers from Tanzania and South Africa, who are part of the Cochrane Infectious Disease Group, hosted at LSTM, have conducted an independent review to assess the effect of intermittent preventive antimalarial treatment (IPT) for children with anaemia living in malaria endemic regions. This is a strategy of giving a treatment dose of antimalarial drugs to children at regular intervals just in case they have become infected.

15 Jan 2015

Endocrinology Network offers up-to-date coverage of SGLT2 inhibitors

UBM Medica US announces that Endocrinology Network, a leading online community for endocrinologists and other clinicians who treat patients with T2DM offers comprehensive and up-to-date coverage of the sodium glucose cotransporter 2 (SGLT2) inhibitors.

15 Jan 2015

How quickly smokers metabolise nicotine may point to best quitting method

The success of different smoking cessation treatments could be predicted by how quickly smokers break down (metabolise) nicotine in their bodies, according to new research published in The Lancet Respiratory Medicine journal.

13 Jan 2015

MGB Biopharma provides update on business performance for 2014

MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, provides an update on its business performance for 2014. MGB Biopharma is developing a pipeline of novel antimicrobials that puts it at the forefront of addressing the major global problem of antimicrobial resistance.

12 Jan 2015

EMA accepts Praluent (alirocumab) MAA for review

Regeneron and Sanofi today announced that the European Medicines Agency has accepted for review the Marketing Authorization Application for Praluent (alirocumab). Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) that is intended for the treatment of patients with hypercholesterolemia.

12 Jan 2015

Two new ODYSSEY trials meet primary efficacy endpoints

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that two new ODYSSEY trials, which are the first Phase 3 trials to assess alirocumab administered every four weeks, met their primary efficacy endpoints.

9 Jan 2015

Man-made insulin nasal spray may improve memory in adults with Alzheimer's-related dementia

A man-made form of insulin delivered by nasal spray may improve working memory and other mental capabilities in adults with mild cognitive impairment and Alzheimer's disease dementia, according to a pilot study led by researchers at Wake Forest Baptist Medical Center.

9 Jan 2015

Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration has approved SAVAYSA (edoxaban) Tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF).

8 Jan 2015

One cup of blueberries per day could help reduce blood pressure, arterial stiffness

Just one cup of blueberries per day could be the key to reducing blood pressure and arterial stiffness, both of which are associated with cardiovascular disease.

8 Jan 2015

FDA approves RYTARY for Parkinson's disease treatment

Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.

8 Jan 2015

Ferrer partners with Cipher Pharmaceuticals to bring Ozenoxacin to the Canadian market

Ferrer, a privately-held Spanish pharmaceutical company, today announces that it has licensed commercialisation rights for Ozenoxacin one per cent cream in Canada to Cipher Pharmaceuticals Inc.

8 Jan 2015

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) has received "Fast Track" designation from the US Food and Drug Administration.

7 Jan 2015

Johnson & Johnson begins Phase 1 trial of preventive Ebola vaccine program

Johnson & Johnson today announced the start of a Phase 1, first-in-human clinical trial of a preventive Ebola vaccine in development at its Janssen Pharmaceutical Companies.

6 Jan 2015

BrainStorm's phase 2a ALS study meets primary endpoint

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced positive final results from its phase 2a clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS) patients, which enrolled 14 subjects at Hadassah Medical Center in Jerusalem.

6 Jan 2015

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.

31 Dec 2014

Placebo News and Research

AHS provides updated assessment of treatments for acute migraine

LUME-Lung 1 shows QoL, symptoms benefits

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Penn State researchers explore benefits of beet juice

GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

Researchers assess the effect of IPT for children with anaemia in malaria endemic regions

Endocrinology Network offers up-to-date coverage of SGLT2 inhibitors

How quickly smokers metabolise nicotine may point to best quitting method

MGB Biopharma provides update on business performance for 2014

EMA accepts Praluent (alirocumab) MAA for review

Two new ODYSSEY trials meet primary efficacy endpoints

Man-made insulin nasal spray may improve memory in adults with Alzheimer's-related dementia

Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

One cup of blueberries per day could help reduce blood pressure, arterial stiffness

FDA approves RYTARY for Parkinson's disease treatment

Ferrer partners with Cipher Pharmaceuticals to bring Ozenoxacin to the Canadian market

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Johnson & Johnson begins Phase 1 trial of preventive Ebola vaccine program

BrainStorm's phase 2a ALS study meets primary endpoint

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News